Director

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Institution	Shares	Value	Change
VANGUARD CAPITAL MANAGEMENT LLC	4,389,119	$752M	NEW
BlackRock, Inc.	4,289,924	$735M	DECREASED
Capital World Investors	4,072,296	$698M	INCREASED
Capital International Investors	3,809,202	$653M	DECREASED
VANGUARD PORTFOLIO MANAGEMENT LLC	3,150,783	$540M	NEW

Insider	Type	Shares	Date
MORROW GEORGE J (Director)	EXERCISE	1,745	2026-05-20
Kevin T Conroy (Director)	AWARD	1,836	2026-05-20
Kevin T Conroy (Director)	EXERCISE	1,745	2026-05-20
Joseph Lacob (Director)	AWARD	1,836	2026-05-20
Joseph Lacob (Director)	EXERCISE	1,745	2026-05-20

Align Technology Inc (ALGN) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades